SDC1 and Miyoshi myopathy: SL1 can serve not only as a molecular probe to selectively recognize cellular c‐met with high affinity in vitro and in vivo, but it can also serve as a therapeutic antagonist for c‐met positive MM cell lines and primary CD138+ MM cells from clinical samples through the inhibition of HGF‐induced c‐met signaling.